HeartCore Reports Full Year 2025 Results

Rhea-AI Summary

HeartCore (Nasdaq: HTCR) reported full-year 2025 results reflecting a strategic shift from software to financial services and capital markets advisory.

Key points: Revenue $9.0M (down from $22.7M), gross profit $3.2M, net income $5.5M driven by the sale of HeartCore Japan, adjusted EBITDA $6.5M, cash $2.0M. Company authorized a one-time distribution, a $2.0M share repurchase program, divested HeartCore Japan, and established Higgs Field on October 31, 2025.

Positive

• Net income of $5.5M driven by sale of HeartCore Japan
• Adjusted EBITDA of $6.5M, remaining positive
• Authorized $2.0M share repurchase program
• 16 Go IPO clients under engagement, including 6 in registration stages

Negative

• Revenue down from $22.7M to $9.0M (≈60% decline)
• Gross profit fell from $14.7M to $3.2M (≈78% decline)
• Adjusted EBITDA declined from $7.3M to $6.5M (≈11% drop)
• Cash and cash equivalents of $2.0M at December 31, 2025

Market Reaction – HTCR

-6.33% $0.21 1.9x vol

15m delay 5 alerts

-6.33% Since News

+7.2% Peak in 0 min

$0.21 Last Price

$0.20 $0.27 Day Range

-$385K Valuation Impact

$5.70M Market Cap

1.9x Rel. Volume

Following this news, HTCR has declined 6.33%, reflecting a notable negative market reaction. Argus tracked a peak move of +7.2% during the session. Our momentum scanner has triggered 5 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.21. This price movement has removed approximately $385K from the company's valuation. Trading volume is above average at 1.9x the average, suggesting increased trading activity.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Full-year 2025 revenue: $9.0 million Full-year 2025 gross profit: $3.2 million Operating expenses: $6.3 million +5 more

8 metrics

Full-year 2025 revenue $9.0 million Year ended December 31, 2025; vs $22.7 million prior year

Full-year 2025 gross profit $3.2 million Year ended December 31, 2025; vs $14.7 million prior year

Operating expenses $6.3 million Full year 2025; vs $14.9 million prior year

Net income $5.5 million Full year 2025; vs $5.2 million net loss prior year

Adjusted EBITDA $6.5 million Full year 2025; vs $7.3 million prior year

Cash and equivalents $2.0 million Balance as of December 31, 2025

Go IPO clients 16 clients Engaged as of March 31, 2026

Share repurchase program $2.0 million Authorization for common stock buybacks

Market Reality Check

Price: $0.2243 Vol: Volume 151,758 is below t...

normal vol

$0.2243 Last Close

Volume Volume 151,758 is below the 20-day average of 188,375, suggesting no outsized trading response pre‑announcement. normal

Technical Shares at $0.2243 are trading below the $0.53 200-day MA and sit near the $0.2142 52-week low, far from the $1.67 high.

Peers on Argus

HTCR was down about 4.6% while momentum‑flagged peers SAGT, AIXI, CXAI and NXPL ...

4 Up

HTCR was down about 4.6% while momentum‑flagged peers SAGT, AIXI, CXAI and NXPL showed gains between roughly 1.6% and 4.9%, indicating stock-specific pressure rather than a sector-wide selloff.

Previous Earnings Reports

5 past events · Latest: Feb 11 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 11	Prelim FY25 results	Positive	-1.7%	Preliminary FY25 outlook showing profitability despite revenue decline after divestiture.
Nov 18	Q3 2025 results	Negative	-18.7%	Q3 revenue drop and reclassification of HeartCore Japan as discontinued operations.
Aug 13	Q2 2025 results	Positive	+8.1%	Return to profitability with higher Q2 revenue and gross profit growth.
May 15	Q1 2025 results	Negative	-17.6%	Revenue decline, wider net loss, and weaker cash position in Q1 2025.
Mar 31	2024 annual results	Negative	-12.5%	Strong 2024 growth but goodwill impairment and net loss weighed on sentiment.

Pattern Detected

Earnings releases have often coincided with negative price reactions, even when results showed profitability or growth.

Recent Company History

Over the past year, HeartCore’s earnings cycle has featured volatility. FY 2024 results showed strong revenue and gross profit growth but a net loss, followed by mixed quarterly trends with Q1 weakness and a profitable Q2 2025. Later in 2025, results incorporated the divestiture of HeartCore Japan and a shift toward Go IPO consulting, with markets generally reacting negatively to these earnings updates. Today’s FY 2025 report, showing lower revenue but positive net income driven by the sale, fits this ongoing transformation narrative.

Historical Comparison

-8.5% avg move · Across 5 prior earnings releases, HTCR’s average move was about -8.49%. Today’s roughly -4.6% pre‑ne...

earnings

-8.5%

Average Historical Move earnings

Across 5 prior earnings releases, HTCR’s average move was about -8.49%. Today’s roughly -4.6% pre‑news slide fits the pattern of cautious reactions to results.

Earnings have tracked HeartCore’s shift from software-led growth in 2024 to a 2025 model built around Go IPO consulting and the HeartCore Japan divestiture, moving from losses to profitability despite a smaller revenue base.

Market Pulse Summary

The stock is down -6.3% following this news. A negative reaction despite profitable full-year 2025 r...

Analysis

The stock is down -6.3% following this news. A negative reaction despite profitable full-year 2025 results fits the pattern of cautious responses to HeartCore’s earnings. Revenue fell to $9.0 million from $22.7 million, and gross profit declined sharply, even though net income reached $5.5 million on the HeartCore Japan sale. Shares were already far below the $1.67 52-week high and close to the $0.2142 low, so disappointment in the smaller ongoing business could have reinforced downside pressure.

Key Terms

adjusted EBITDA

1 terms

adjusted EBITDA financial

"Adjusted EBITDA was $6.5 million, compared to $7.3 million in the same period..."

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

AI-generated analysis. Not financial advice.

NEW YORK and TOKYO, March 31, 2026 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or the “Company”), an IPO consulting services company based in Tokyo, reported financial results for the full year ended December 31, 2025.

Recent Operational Highlights

• As of March 31, 2026, HeartCore was engaged with 16 Go IPO clients, including 6 clients currently in various stages of preparation for potential public registrations and U.S. exchange listings.
• Authorized one-time distribution payment to stockholders.
• Authorized $2.0 million share repurchase program.
• Divested software business subsidiary, HeartCore Co., Ltd (“HeartCore Japan”).
• Established Higgs Field Co., Ltd. (“Higgs Field”) on October 31, 2025, as a new subsidiary in Japan to support the Company’s strategic transition toward financial services.
  

Management Commentary

HeartCore CEO Sumitaka Kanno commented:“Over the past year, we executed a strategic transformation of our business, including the divestiture of our software business subsidiary, HeartCore Japan, and a shift toward financial services and capital markets-related activities. We have also made progress in our Go IPO business, with an expanding client base and multiple engagements advancing through various stages of the registration and listing process. In addition, we established Higgs Field in the fourth quarter of 2025 to serve as our new operating platform in Japan. Going forward, we will continue to strengthen our focus on financial services and aim to drive sustainable growth and long-term stockholder value.”

Full Year 2025 Financial Results
Revenues were $9.0 million, compared to $22.7 million in the same period last year. The decrease was primarily due to receipt of $13 million in warrant revenue from one large Go IPO deal in the prior period, and no comparable revenue in the current period.

Gross profit was $3.2 million, compared to $14.7 million in the same period last year. The decrease was primarily due to the absence of a significant warrant-related revenue contribution from a large Go IPO deal recognized in the prior period.

Operating expenses decreased to $6.3 million, compared to $14.9 million in the same period last year. The decrease was primarily due to the reduction in operating expenses to save cash flows and the absence of impairment charges for intangible assets and goodwill during the current period.

Net income was $5.5 million, compared to a net loss of $5.2 million in the same period last year. The increase was primarily due to the gain on the sale of HeartCore Japan.

Adjusted EBITDA was $6.5 million, compared to $7.3 million in the same period last year.

As of December 31, 2025, the Company had cash and cash equivalents of $2.0 million.

About HeartCore Enterprises, Inc.
HeartCore Enterprises, Inc. is headquartered in Tokyo, Japan, and is a leading consulting services company providing U.S. market listing support and related advisory services primarily to Japanese corporate clients. For more information, please visit https://heartcore-enterprises.com/.

Non-GAAP Financial Measures
This document includes references to adjusted EBITDA, which is a non-GAAP financial measure. For the purposes of this presentation, adjusted EBITDA is calculated by adjusting net loss to exclude depreciation and amortization, changes in fair value of investments in marketable securities, changes in fair value of investment in warrants, interest income, and interest expenses.

This measure is presented as supplemental information and is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”).

Management believes that adjusted EBITDA provides useful information to investors by highlighting the Company’s core operational performance, excluding non-cash and non-recurring items. However, non-GAAP financial measures have limitations and should not be considered in isolation or as a substitute for financial results prepared in accordance with GAAP.

Item	FY25	FY24
Net income (loss)	$5.5 million	$(5.2) million
(+) Depreciation	$0.0 million	$0.1 million
(+) Impairment loss on goodwill	$0.0 million	$3.3 million
(+) Impairment loss on intangible assets	$0.0 million	$3.9 million
(+) Changes in fair value of investments in marketable securities	$1.5 million	$2.4 million
(+) Changes in fair value of investment in warrants	$(0.6) million	$(1.7) million
(+) Loss on sale of warrants	$0.0 million	$4.0 million
(+) Impairment of investment in equity securities	$0.0 million	$0.3 million
(+) Changes in fair value of derivative liability	$(0.1) million	$0.0 million
(+) Loss on forgiveness of note receivable	$0.1 million	$0.1 million
(+) Interest income	$(0.0) million	$(0.0) million
(+) Interest expenses	$0.1 million	$0.1 million
Adjusted EBITDA	$6.5 million	$7.3 million

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, or the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believed,” “intend,” “expect,” “anticipate,” “plan,” “potential,” “continue,” or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks, and uncertainties are discussed in HeartCore’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond HeartCore’s control which could, and likely will materially affect actual results, and levels of activity, performance, or achievements. Any forward-looking statement reflects HeartCore’s current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. HeartCore assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

HeartCore Investor Relations Contact:
Gateway Group, Inc.
John Yi and Steven Shinmachi
HTCR@gateway-grp.com
(949) 574-3860

HeartCore Enterprises, Inc.
Consolidated Balance Sheets
		December 31,				December 31,
		2025				2024
ASSETS
Current assets:
Cash and cash equivalents	$	1,985,962			$	1,973,810
Accounts receivable		707,865				1,030,243
Investments in marketable securities		3,690,187				4,495,703
Prepaid expenses		182,077				131,325
Current portion of long-term note receivable		100,000				100,000
Deferred offering costs		250,000				-
Other current assets		208,503				136,217
Current assets of discontinued operations		-				1,550,067
Proceeds receivable from sale of discontinued operations		1,291,298				-
Total current assets		8,415,892				9,417,365
Non-current assets:
Property and equipment, net		291,589				475,697
Operating lease right-of-use assets		29,449				172,594
Long-term investment in warrants		280,924				577,786
Long-term note receivable		-				100,000
Deferred tax assets		23,121				31,575
Security deposits		282,958				108,880
Other non-current assets		549				11,715
Non-current assets of discontinued operations		-				3,069,422
Long-term proceeds receivable from sale of discontinued operations		3,736,995				-
Total non-current assets		4,645,585				4,547,669
Total assets	$	13,061,477			$	13,965,034
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	1,146,501			$	1,637,108
Accounts payable and accrued expenses - related party		124,618				47,199
Accrued payroll and other employee costs		509,547				273,115
Due to related party		285				885
Short-term debt - related party		75,000				75,000
Current portion of long-term debts		50,598				46,382
Insurance premium financing		13,430				16,626
Factoring liability		135,982				172,394
Operating lease liabilities, current		32,793				134,910
Finance lease liabilities, current		-				15,956
Income tax payables		1,857,386				818,030
Deferred revenue		676,216				751,251
Derivative liability		121,719				-
Other current liabilities		586,175				589,762
Current liabilities of discontinued operations		-				2,843,104
Total current liabilities		5,330,250				7,421,722
Non-current liabilities:
Long-term debts		448,376				498,706
Operating lease liabilities, non-current		-				41,530
Finance lease liabilities, non-current		-				43,593
Asset retirement obligations		-				72,463
Non-current liabilities of discontinued operations		-				2,425,005
Total non-current liabilities		448,376				3,081,297
Total liabilities		5,778,626				10,503,019
Shareholders' equity:
Preferred shares, $0.0001 par value, 20,000,000 shares authorized; Series A convertible preferred shares, 4,000 and no shares designated, 1,017 and no shares issued and outstanding as of December 31, 2025 and 2024, respectively; aggregate liquidation preference of $1,158,362 and nil as of December 31, 2025 and 2024, respectively		691,858				-
Common shares, $0.0001 par value, 200,000,000 shares authorized, 25,419,807 and 21,937,987 shares issued and outstanding as of December 31, 2025 and 2024, respectively		2,542				2,193
Subscription receivable		-				(103,942	)
Additional paid-in capital		21,899,754				20,656,153
Accumulated deficit		(13,755,534	)			(16,244,843	)
Accumulated other comprehensive income (loss)		(58,497	)			343,936
Total HeartCore Enterprises, Inc. shareholders' equity		8,780,123				4,653,497
Non-controlling interests		(1,497,272	)			(1,191,482	)
Total shareholders' equity		7,282,851				3,462,015
Total liabilities and shareholders' equity	$	13,061,477			$	13,965,034

HeartCore Enterprises, Inc.
Consolidated Statements of Operations and Comprehensive Income (Loss)
		For the Years Ended December 31,
		2025				2024
Revenues	$	8,968,732			$	22,685,544
Cost of revenues (including cost of revenues resulting from transactions with a related party of $261,257 and $160,502 for the years ended December 31, 2025 and 2024, respectively)		5,817,279				7,969,898
Gross profit		3,151,453				14,715,646
Operating expenses:
Selling expenses		233,744				621,070
General and administrative expenses (including general and administrative expenses resulting from transactions with a related party of $29,048 and $41,786 for the years ended December 31, 2025 and 2024, respectively)		6,039,026				6,921,959
Research and development expenses		-				179,762
Impairment of intangible asset		-				3,878,125
Impairment of goodwill		-				3,276,441
Total operating expenses		6,272,770				14,877,357
Loss from continuing operations		(3,121,317	)			(161,711	)
Other income (expenses):
Changes in fair value of investments in marketable securities		(1,494,234	)			(2,412,385	)
Changes in fair value of investments in warrants		625,675				1,657,699
Loss on sale of warrants		-				(3,970,628	)
Impairment of investment in equity securities		-				(300,000	)
Changes in fair value of derivative liability		114,422				-
Loss on forgiveness of note receivable		(100,000	)			(100,000	)
Interest income		5,381				15,882
Interest expenses		(87,660	)			(118,789	)
Other income		100,233				32,042
Other expenses		(181,605	)			(153,917	)
Total other expenses		(1,017,788	)			(5,350,096	)
Loss from continuing operations before income tax expense (benefit)		(4,139,105	)			(5,511,807	)
Income tax expense (benefit)		44,900				(363,156	)
Net loss from continuing operations		(4,184,005	)			(5,148,651	)
Income (loss) from discontinued operations, net of income tax		9,677,293				(64,249	)
Net income (loss)		5,493,288				(5,212,900	)
Less: net loss attributable to non-controlling interests		(300,596	)			(3,731,526	)
Net income (loss) attributable to HeartCore Enterprises, Inc.		5,793,884				(1,481,374	)
Dividends accrued on Series A convertible preferred shares		(94,357	)			-
Net income (loss) attributable to HeartCore Enterprises, Inc. common shareholders	$	5,699,527			$	(1,481,374	)
Other comprehensive loss:
Foreign currency translation adjustment		(152,969	)			(16,614	)
Total comprehensive income (loss)		5,340,319				(5,229,514	)
Less: comprehensive loss attributable to non-controlling interests		(305,790	)			(3,760,195	)
Comprehensive income (loss) attributable to HeartCore Enterprises, Inc.	$	5,646,109			$	(1,469,319	)
Net income (loss) from continuing operations attributable to HeartCore Enterprises, Inc. per common share
Basic	$	(0.17	)		$	(0.07	)
Diluted	$	(0.17	)		$	(0.07	)
Income (loss) from discontinued operations per common share
Basic	$	0.42			$	(0.00	)
Diluted	$	0.38			$	(0.00	)
Net income (loss) attributable to HeartCore Enterprises, Inc. per common share
Basic	$	0.25			$	(0.07	)
Diluted	$	0.22			$	(0.07	)
Weighted average common shares outstanding
Basic		23,072,519				20,940,956
Diluted		25,459,388				20,940,956

HeartCore Enterprises, Inc.
Consolidated Statements of Cash Flows
		For the year ended December 31,
		2025				2024
Cash flows from operating activities of continuing operations:
Net income	$	5,493,288			$	(5,212,900	)
Income from discontinued operations, net of income tax		9,677,293				(64,249	)
Net loss from continuing operations		(4,184,005	)			(5,148,651	)
Adjustments to reconcile net loss from continuing operations to net cash flows
used in operating activities of continuing operations:
Depreciation and amortization expenses		46,373				676,047
Loss on disposal of property and equipment		116,981				1,798
Non-cash lease expense		62,845				126,217
Gain on termination of lease		(9,059	)			-
Impairment of intangible asset		-				3,878,125
Impairment of goodwill		-				3,276,441
Deferred income taxes		9,192				(1,297,495	)
Stock-based compensation		(151,139	)			368,744
Marketable securities received as noncash consideration		-				(572,010	)
Warrants received as noncash consideration		(837,913	)			(12,969,683	)
Changes in fair value of investments in marketable securities		1,494,234				2,412,385
Changes in fair value of investment in warrants		(625,675	)			(1,657,699	)
Loss on sale of warrants		-				3,970,628
Impairment of investment in equity securities		-				300,000
Impairment of investment in SAFE		-				75,000
Changes in fair value of derivative liability		(114,422	)			-
Loss on forgiveness of note receivable		100,000				100,000
Gain on settlement of asset retirement obligations		(45,873	)			-
Changes in assets and liabilities:
Accounts receivable		322,040				1,050,522
Prepaid expenses		86,563				178,949
Other assets		(119,413	)			71,469
Accounts payable and accrued expenses		(485,665	)			318,803
Accounts payable and accrued expenses - related party		79,600				47,955
Accrued payroll and other employee costs		234,835				(59,033	)
Due to related party		(585	)			-
Operating lease liabilities		(54,400	)			(131,935	)
Income tax payables		1,036,456				667,483
Deferred revenue		(75,035	)			(98,145	)
Other liabilities		(3,036	)			523,768
Net cash flows used in operating activities of continuing operations		(3,117,101	)			(3,890,317	)
Cash flows from investing activities of continuing operations:
Purchase of investment in SAFE		-				(75,000	)
Net proceeds from sale of warrants		-				5,640,000
Proceeds from sale of marketable securities		1,071,732				749,546
Proceeds from sale of discontinued operations, net of cash divested		4,518,868				-
Net cash flows provided by investing activities of continuing operations		5,590,600				6,314,546
Cash flows from financing activities of continuing operations:
Payments for finance lease		(14,666	)			(16,518	)
Proceeds from related party debt		-				75,000
Repayment of long-term debts		(46,114	)			(33,919	)
Repayment of insurance premium financing		(142,696	)			(156,063	)
Net repayment of factoring arrangement		(36,412	)			(390,373	)
Capital contribution from non-controlling shareholder		-				67,195
Dividends paid for common shares		(3,304,575	)			(834,566	)
Proceeds from issuance of common shares related to at the market offering agreement		30,445				1,423,342
Proceeds from collection of subscription receivable		103,942				-
Proceeds from exercise of stock options		117,000				-
Proceeds from issuance of Series A convertible preferred shares and common shares related to securities purchase agreement, net of share issuance costs		1,800,000				-
Net cash flows provided by (used in) financing activities of continuing operations		(1,493,076	)			134,098
Cash flows from discontinued operations:
Net cash flows used in operating activities of discontinued operations		(854,831	)			(884,654	)
Net cash flows provided by investing activities of discontinued operations		171,641				34,658
Net cash flows used in financing activities of discontinued operations		(351,089	)			(452,744	)
Net cash flows used in discontinued operations		(1,034,279	)			(1,302,740	)
Effect of exchange rate changes		(81,271	)			(146,977	)
Net change in cash and cash equivalents		(135,127	)			1,108,610
Cash and cash equivalents - beginning of the year		2,121,089				1,012,479
Cash and cash equivalents - end of the year	$	1,985,962			$	2,121,089
Supplemental cash flow disclosures:
Interest paid	$	109,440			$	143,101
Income taxes paid	$	211,844			$	298,466
Non-cash investing and financing transactions:
Insurance premium financing	$	139,500			$	172,689
Warrants converted to marketable securities	$	1,760,450			$	6,443,276
Issuance of common shares related to equity purchase agreement	$	250,000			$	-
Dividends accrued on Series A convertible preferred shares	$	94,357			$	-
Issuance of common shares for dividends on Series A convertible preferred shares	$	220,000			$	-
Series A convertible preferred shares converted to common shares	$	668,728			$	-

FAQ

What were HeartCore's (HTCR) full-year 2025 revenues and how do they compare to 2024?

HeartCore reported $9.0 million in revenue for 2025, down substantially from $22.7 million in 2024. According to the company, the decline reflects the absence of a prior-period $13 million warrant-related revenue contribution.

Why did HeartCore (HTCR) report net income of $5.5M in 2025 despite lower revenue?

Net income was $5.5 million largely due to a gain on the sale of HeartCore Japan. According to the company, the divestiture offset reduced operating performance and produced the reported profit.

What corporate actions did HeartCore (HTCR) authorize on March 31, 2026?

The company authorized a one-time distribution to stockholders and a $2.0 million share repurchase program. According to the company, these actions target returning capital while the business shifts focus.

How did HeartCore's (HTCR) profitability metrics change in 2025?

Gross profit decreased to $3.2 million and adjusted EBITDA fell to $6.5 million. According to the company, the changes reflect the lack of a major warrant-related revenue item in 2025.

What strategic moves did HeartCore (HTCR) make in 2025 to shift its business?

HeartCore divested its software subsidiary and established Higgs Field on October 31, 2025 to pivot toward financial services. According to the company, this supports its transition into capital markets-related activities.

How many Go IPO clients does HeartCore (HTCR) have and what stages are they in?

As of March 31, 2026, HeartCore was engaged with 16 Go IPO clients, including 6 clients in various stages of preparation for potential public registrations and U.S. listings, according to the company.